TY - JOUR
T1 - Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems
AU - Kondo, Eisaku
AU - Saito, Ken
AU - Tashiro, Yuichi
AU - Kamide, Kaeko
AU - Uno, Shusei
AU - Furuya, Tomoko
AU - Mashita, Masao
AU - Nakajima, Kiichiro
AU - Tsumuraya, Tomoyuki
AU - Kobayashi, Naoya
AU - Nishibori, Masahiro
AU - Tanimoto, Mitsune
AU - Matsushita, Masayuki
N1 - Funding Information:
We thank Dr. Kyl Myrick (Department of Molecular and Cellular Biology, Harvard University) for critical reading of the manuscript, Dr. Sadayo Iijima (Mitsubishi Chemical Holdings) and Ms. Yumiko Kasugai (Aichi Cancer Center Research Institute) for technical support, Dr. Masaki Miyanishi and Dr. Masayuki Takayama (Sigma Aldrich, Japan) for peptide synthesis, Dr. Takayoshi Miyake (Tsuyama Chuo Hospital) and Dr. Tadashi Yoshino (Department of Pathology, Okayama University) for statistical analyses and discussions. Hayashibara Biochemical Laboratories (Okayama, Japan), Dr. Hitoshi Ohno (Takeda General Hospital), and Dr. Hirohisa Yano (Kurume University) kindly provided us with several human tumour cell lines and a GFP-expressing plasmid (pEF-GFP). We thank Dr. Mikako Ogawa (Hamamatsu University School of Medicine) for invaluable advice. This research was supported by the Japan Science and Technology Agency (Adaptable and Seamless Technology Transfer Program through Target-driven R&D to E.K. (principal investigator), and by Grant-in-Aid for Scientific Research on Innovative Areas (E.K.) and Special Account Budget for Education and Research (M.M.) from the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT), the Uehara Memorial Foundation, Takeda Science Foundation (M.M.) and also supported by a grant from the Scientific Reasearch from the Ministry of Health, Labor and Welfare of Japan (M.N.).
PY - 2012
Y1 - 2012
N2 - Cell-penetrating peptides have gained attention owing to their promise in noninvasive delivery systems. Among the identified cell-penetrating peptides, the TAT peptide has been preferentially used for transduction into cells of diverse origins. However, this activity is nonselective between neoplastic and non-neoplastic cells. Here we describe artificial cell-penetrating peptides that are selectively and efficiently incorporated into human tumour cells, according to their lineage. Ten representative tumour lineage-homing cell-penetrating peptides were obtained by screening of a random peptide library constructed using messenger RNA display technology, and some of the isolates were further modified by amino-acid substitution. Their advantageous tumour cell-targeting ability is corroborated in an in vivo mouse model for imaging and growth suppression of metastatic xenoplant tumours. These cell-penetrating peptides are potentially useful for the efficient targeting of human neoplasms in a tumour origin-dependent manner, and provide a framework for the development of peptide-based anti-tumour technologies.
AB - Cell-penetrating peptides have gained attention owing to their promise in noninvasive delivery systems. Among the identified cell-penetrating peptides, the TAT peptide has been preferentially used for transduction into cells of diverse origins. However, this activity is nonselective between neoplastic and non-neoplastic cells. Here we describe artificial cell-penetrating peptides that are selectively and efficiently incorporated into human tumour cells, according to their lineage. Ten representative tumour lineage-homing cell-penetrating peptides were obtained by screening of a random peptide library constructed using messenger RNA display technology, and some of the isolates were further modified by amino-acid substitution. Their advantageous tumour cell-targeting ability is corroborated in an in vivo mouse model for imaging and growth suppression of metastatic xenoplant tumours. These cell-penetrating peptides are potentially useful for the efficient targeting of human neoplasms in a tumour origin-dependent manner, and provide a framework for the development of peptide-based anti-tumour technologies.
UR - http://www.scopus.com/inward/record.url?scp=84864839075&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864839075&partnerID=8YFLogxK
U2 - 10.1038/ncomms1952
DO - 10.1038/ncomms1952
M3 - Article
C2 - 22805558
AN - SCOPUS:84864839075
SN - 2041-1723
VL - 3
JO - Nature communications
JF - Nature communications
M1 - 951
ER -